(Q33346173)
Statements
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer (English)
Henry C Pitot
Grace K Dy
Alex A Adjei
Lorelei J Hanson
Charles Erlichman
Pamela J Atherton
Steven R Alberts
Joel M Reid
Richard M Goldberg
Tanya Watanabe
Richard S Geary
Jon Holmlund